A detailed history of Allianz Asset Management Gmb H transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 77,934 shares of CPRX stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,934
Previous 92,391 15.65%
Holding current value
$1.71 Million
Previous $1.43 Million 8.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.19 - $21.35 $219,601 - $308,656
-14,457 Reduced 15.65%
77,934 $1.55 Million
Q2 2024

Aug 13, 2024

SELL
$14.68 - $16.92 $82,046 - $94,565
-5,589 Reduced 5.7%
92,391 $1.43 Million
Q1 2024

May 13, 2024

BUY
$13.18 - $17.11 $511,990 - $664,655
38,846 Added 65.69%
97,980 $1.56 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $410,576 - $527,532
-35,122 Reduced 37.26%
59,134 $691,000
Q2 2023

Aug 11, 2023

SELL
$11.5 - $18.08 $3.17 Million - $4.99 Million
-275,801 Reduced 74.53%
94,256 $1.27 Million
Q1 2023

May 11, 2023

SELL
$14.34 - $21.05 $613,436 - $900,476
-42,778 Reduced 10.36%
370,057 $6.14 Million
Q4 2022

Feb 13, 2023

BUY
$12.25 - $19.5 $261,304 - $415,954
21,331 Added 5.45%
412,835 $7.68 Million
Q3 2022

Nov 08, 2022

SELL
$7.06 - $15.52 $4.58 Million - $10.1 Million
-648,041 Reduced 62.34%
391,504 $5.02 Million
Q2 2022

Aug 12, 2022

BUY
$6.23 - $8.57 $772,644 - $1.06 Million
124,020 Added 13.55%
1,039,545 $7.29 Million
Q1 2022

May 13, 2022

BUY
$5.31 - $8.31 $4.67 Million - $7.3 Million
878,795 Added 2392.58%
915,525 $7.59 Million
Q4 2021

Feb 11, 2022

BUY
$5.21 - $7.45 $4,162 - $5,952
799 Added 2.22%
36,730 $249,000
Q3 2021

Nov 10, 2021

SELL
$4.85 - $6.04 $286,319 - $356,571
-59,035 Reduced 62.16%
35,931 $190,000
Q2 2021

Aug 16, 2021

BUY
$4.29 - $6.05 $407,404 - $574,544
94,966 New
94,966 $546,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.25B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.